Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19944871 | 0.88 | CYP2D6 (0.43) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL13471107 | 0.88 | CYP2D6 (0.43) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL19944483 | 0.78 | CTSK (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL18471339 | 0.78 | CTSK (0.43) | CTSK | |
| SCHEMBL19944461 | 0.77 | CYP2D6 (0.33) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL1401278 | 0.77 | CTSK (0.57) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL27640544 | 0.77 | CTSK (0.57) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL3498487 | 0.76 | CTSK (0.63) | CTSK | |
| SCHEMBL13471217 | 0.76 | CTSK (0.63) | CTSK | |
| SCHEMBL20349139 | 0.72 | CYP2D6 (0.35) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2021-04-13 | — | — | US | disclosed |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-07-05 | — | — | US | disclosed |
| EP-2697246-B1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, SERPINE1, CASP5 | CTSK 138/4885CYP1A2 2156/4885CYP2C9 1709/4885 |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | SERPINB1, SERPINE1, CASP5 | CTSK 128/4885CYP1A2 2138/4885CYP2C9 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.